Physician profile
Margot E Vloka
NPI 1174517775
$103,608.86
in general payments reported to CMS, 2019-2025
19 companies · $3,464 in 2025
The $3,464 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $14K · 2021: $19K · 2022: $14K · 2023: $20K · 2024: $12K · 2025: $3,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $20K · Consulting Fee: $9,225 · Food and Beverage: $3,939 · Travel and Lodging: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $19,562.28 |
| Consulting Fee | $9,225.00 |
| Food and Beverage | $3,939.25 |
| Travel and Lodging | $2,644.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| B. Braun Melsungen Ag | $57,816.03 | 2019-2024 | Contiplex |
| Atricure, INC. | $27,339.90 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Acutus Medical, INC. | $4,389.60 | 2019-2023 | |
| Medtronic, INC. | $3,792.47 | 2021-2025 | Evera Mri Xt Dr Surescan, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $2,878.32 | 2019-2025 | Versacross Steerable Access Solution, Watchman Access System, Farapulse |
| Medtronic Vascular, INC. | $2,392.77 | 2019-2020 | |
| Stereotaxis INC | $1,694.62 | 2019-2023 | Niobe |
| Biotronik INC. | $1,664.92 | 2019-2025 | Amvia Edge, Acticor 7 Vr-T Dx |
| Biosense Webster, INC. | $1,123.33 | 2019-2024 | Carto 3, Qdot Micro Catheter, Octaray Mapping Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.25 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $80.41 | 2019-2022 | |
| Abbott Laboratories | $77.29 | 2022-2025 | Gallant, Ensite |
| Cardiva Medical, INC. | $54.33 | 2023 | Cardiva Vascade 6/7f Vcs |
| Novartis Pharmaceuticals Corporation | $52.01 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $42.55 | 2019-2023 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $32.26 | 2024 | Pascal |
| Amgen INC. | $27.70 | 2019 | |
| Livanova USA, INC. | $23.10 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margot Vloka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.